Table 5 |
|||
|
Logistic regression analysis of FcγRIIa-H/R131 genotypes in relation to anti-malarial IgG subclasses in Fulani compared with non-Fulani groups |
|||
|
Anti-malarial antibodies |
FcγRIIa-H/R131 genotypes |
OR† (95% CI) |
p value |
|
|
|||
|
AMA-1 |
|||
|
IgG1 |
H/H |
0.04 (0.02–0.12) |
< 0.001 |
|
H/R |
1 |
||
|
R/R |
0.86 (0.42–1.78) |
0.69 |
|
|
|
|||
|
IgG2 |
H/H |
0.70 (0.35–1.37) |
0.30 |
|
H/R |
1 |
||
|
R/R |
0.61 (0.34–1.11) |
0.10 |
|
|
|
|||
|
IgG3 |
H/H |
0.31 (0.17–0.57) |
< 0.001 |
|
H/R |
1 |
||
|
R/R |
0.69 (0.34–1.38) |
0.30 |
|
|
|
|||
|
IgG4 |
H/H |
0.59 (0.30–1.15) |
0.12 |
|
H/R |
1 |
||
|
R/R |
0.90 (0.41–1.95) |
0.78 |
|
|
|
|||
|
3D7-MSP2 |
|||
|
IgG1 |
H/H |
0.10 (0.03–0.20) |
< 0.001 |
|
H/R |
1 |
||
|
R/R |
0.86 (0.41–1.80) |
0.69 |
|
|
|
|||
|
IgG2 |
H/H |
2.43 (1.32–4.47) |
< 0.001 |
|
H/R |
1 |
||
|
R/R |
0.83 (0.41–1.69) |
0.61 |
|
|
|
|||
|
IgG3 |
H/H |
0.49 (0.26–0.91) |
0.03 |
|
H/R |
1 |
||
|
R/R |
0.81 (0.40–1.63) |
0.55 |
|
|
|
|||
|
IgG4 |
H/H |
2.76 (1.45–5.26) |
< 0.001 |
|
H/R |
1 |
||
|
R/R |
0.59 (0.28–1.25) |
0.17 |
|
|
|
|||
|
FC27-MSP2 |
|||
|
IgG1 |
H/H |
0.53 (0.28–1.01) |
0.10 |
|
H/R |
1 |
||
|
R/R |
0.86 (0.42–1.78) |
0.68 |
|
|
|
|||
|
IgG2 |
H/H |
0.45 (0.24–0.85) |
0.01 |
|
H/R |
1 |
||
|
R/R |
0.70 (0.35–1.37) |
0.30 |
|
|
|
|||
|
IgG3 |
H/H |
0.13 (0.10–0.26) |
0.01 |
|
H/R |
1 |
||
|
R/R |
0.76 (0.37–1.57) |
0.46 |
|
|
|
|||
|
IgG4 |
H/H |
0.70 (0.36–1.39) |
0.31 |
|
H/R |
1 |
||
|
R/R |
0.97 (0.54–1.74) |
0.92 |
|
|
|
|||
|
Pf332-C231 |
|||
|
IgG1 |
H/H |
1.25 (0.67–2.30) |
0.48 |
|
H/R |
1 |
||
|
R/R |
0.72 (0.36–1.44) |
0.36 |
|
|
|
|||
|
IgG2 |
H/H |
0.22 (0.11–0.44) |
< 0.001 |
|
H/R |
1 |
||
|
R/R |
0.69 (0.34–1.38) |
0.29 |
|
|
|
|||
|
IgG3 |
H/H |
4.25 (2.28–7.91) |
< 0.001 |
|
H/R |
1 |
||
|
R/R |
0.91 (0.45–1.84) |
0.80 |
|
|
|
|||
|
IgG4 |
H/H |
0.10 (0.03–0.20) |
< 0.001 |
|
H/R |
1 |
||
|
R/R |
0.69 (0.26–1.42) |
0.25 |
|
|
|
|||
|
Nasr et al. Malaria Journal 2009 8:43 doi:10.1186/1475-2875-8-43 |
|||